DE60213648D1 - Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln - Google Patents

Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Info

Publication number
DE60213648D1
DE60213648D1 DE60213648T DE60213648T DE60213648D1 DE 60213648 D1 DE60213648 D1 DE 60213648D1 DE 60213648 T DE60213648 T DE 60213648T DE 60213648 T DE60213648 T DE 60213648T DE 60213648 D1 DE60213648 D1 DE 60213648D1
Authority
DE
Germany
Prior art keywords
pain
thymulental
peptides
preparation
thymulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213648T
Other languages
English (en)
Other versions
DE60213648T2 (de
Inventor
Mireille Dardenne
Jean-Marie Pleau
Jean-Francois Bach
Nayef Saade
Bared Safieh-Garabedian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saade Nayef Beirut Lb
Safieh-Garabedian Bared Beirut Lb
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE60213648D1 publication Critical patent/DE60213648D1/de
Application granted granted Critical
Publication of DE60213648T2 publication Critical patent/DE60213648T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60213648T 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln Expired - Lifetime DE60213648T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0112984A FR2830451B1 (fr) 2001-10-09 2001-10-09 Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
FR0112984 2001-10-09
PCT/FR2002/003428 WO2003030927A2 (fr) 2001-10-09 2002-10-08 Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur

Publications (2)

Publication Number Publication Date
DE60213648D1 true DE60213648D1 (de) 2006-09-14
DE60213648T2 DE60213648T2 (de) 2007-08-02

Family

ID=8868083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213648T Expired - Lifetime DE60213648T2 (de) 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Country Status (11)

Country Link
US (1) US7309690B2 (de)
EP (1) EP1450843B1 (de)
JP (1) JP4277684B2 (de)
AT (1) ATE334694T1 (de)
AU (1) AU2002362710B2 (de)
CA (1) CA2463549C (de)
DE (1) DE60213648T2 (de)
ES (1) ES2272811T3 (de)
FR (1) FR2830451B1 (de)
IL (2) IL161319A0 (de)
WO (1) WO2003030927A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
FR2930156B1 (fr) 2008-04-21 2011-10-28 Cll Pharma Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
EP2887964B1 (de) 2012-08-21 2019-07-03 Ardelyx, Inc. Verbindungen und verfahren zur hemmung von nhe-vermitteltem antiport bei der behandlung von erkrankungen im zusammenhang mit flüssigkeitsretention oder salzüberlastung und erkrankungen des gastrointestinaltraktes
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2017210726A1 (en) * 2016-06-06 2017-12-14 Clinical Stem Cells Pty Ltd Peptides for hair growth
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637111A5 (fr) * 1977-05-25 1983-07-15 Anvar Composes polypeptidiques a activite thymique ou antagoniste et leurs procedes de synthese.
DK221681A (da) * 1980-05-22 1981-11-23 Inst Nat Sante Fremgangsmaade til fremstilling af biologisk virksomme og radioimmunologisk anvendelige produkter ud fra serum-thymusfaktoren
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
JPH06192120A (ja) * 1992-12-24 1994-07-12 Mitsui Toatsu Chem Inc 腎臓の組織・細胞の損傷・破壊の予防・治療剤
JP3751986B2 (ja) * 1994-06-21 2006-03-08 英良 横沢 医薬組成物
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US5808009A (en) * 1996-09-23 1998-09-15 North Dakota State University Research Foundation Method of affinity purifying antibodies

Also Published As

Publication number Publication date
CA2463549C (fr) 2011-12-20
EP1450843B1 (de) 2006-08-02
ES2272811T3 (es) 2007-05-01
US7309690B2 (en) 2007-12-18
FR2830451A1 (fr) 2003-04-11
WO2003030927A2 (fr) 2003-04-17
ATE334694T1 (de) 2006-08-15
JP4277684B2 (ja) 2009-06-10
CA2463549A1 (fr) 2003-04-17
EP1450843A2 (de) 2004-09-01
DE60213648T2 (de) 2007-08-02
JP2005515972A (ja) 2005-06-02
FR2830451B1 (fr) 2004-04-30
AU2002362710B8 (en) 2003-04-22
WO2003030927A3 (fr) 2003-10-09
IL161319A0 (en) 2004-09-27
AU2002362710B2 (en) 2007-06-28
IL161319A (en) 2008-11-26
US20050261194A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
DE60213648D1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69934380D1 (de) Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
ATE429922T1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
ATE362485T1 (de) Alloferone - immunomodulierende peptide
AU2002212236A1 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
GB2367061A (en) Peptides
DE69831257D1 (de) Histogranin peptide und deren analgetische verwendung
FI20050753A0 (fi) Uudet peptidit
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69738600D1 (de) Neuroaktive peptide
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
EP1303291A4 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
SE9703287D0 (sv) Peptides
ATE237345T1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ATE446766T1 (de) Verwendung von alpha-s2 casein vorläufer- abgeleiteten peptiden
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks
TW200635953A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SAFIEH-GARABEDIAN, BARED, BEIRUT, LB

Owner name: SAADE, NAYEF, BEIRUT, LB

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, , FR

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

8364 No opposition during term of opposition
8381 Inventor (new situation)

Inventor name: DARDENNE, MIREILLE, F-75015 PARIS, FR

Inventor name: PLEAU, JEAN-MARIE, F-91120 PALAISEAU, FR

Inventor name: BACH, JEAN-FRANCOIS, F-75007 PARIS, FR

Inventor name: SAADE, NAYEF, BEYROUTH, LB

Inventor name: SAFIEH-GARABEDIAN, BARED, 1ST FLOOR, P.O. BOX , LB